|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MRPL37 |
Gene summary for MRPL37 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MRPL37 | Gene ID | 51253 |
| Gene name | mitochondrial ribosomal protein L37 | |
| Gene Alias | L2mt | |
| Cytomap | 1p32.3 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | S4R369 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51253 | MRPL37 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.68e-10 | 4.00e-01 | 0.0155 |
| 51253 | MRPL37 | HTA11_2487_2000001011 | Human | Colorectum | SER | 4.23e-06 | 4.93e-01 | -0.1808 |
| 51253 | MRPL37 | HTA11_2951_2000001011 | Human | Colorectum | AD | 3.04e-02 | 4.49e-01 | 0.0216 |
| 51253 | MRPL37 | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.46e-11 | 6.19e-01 | -0.0811 |
| 51253 | MRPL37 | HTA11_78_2000001011 | Human | Colorectum | AD | 4.73e-08 | 4.79e-01 | -0.1088 |
| 51253 | MRPL37 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.01e-13 | 5.03e-01 | -0.1954 |
| 51253 | MRPL37 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.07e-04 | 7.90e-01 | -0.2602 |
| 51253 | MRPL37 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.06e-04 | 4.75e-01 | -0.1207 |
| 51253 | MRPL37 | HTA11_696_2000001011 | Human | Colorectum | AD | 5.92e-24 | 7.45e-01 | -0.1464 |
| 51253 | MRPL37 | HTA11_866_2000001011 | Human | Colorectum | AD | 4.45e-07 | 3.09e-01 | -0.1001 |
| 51253 | MRPL37 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.28e-21 | 7.99e-01 | -0.059 |
| 51253 | MRPL37 | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.65e-03 | 5.89e-01 | -0.1706 |
| 51253 | MRPL37 | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.25e-04 | 4.43e-01 | -0.2061 |
| 51253 | MRPL37 | HTA11_5216_2000001011 | Human | Colorectum | SER | 7.71e-04 | 4.96e-01 | -0.1462 |
| 51253 | MRPL37 | HTA11_546_2000001011 | Human | Colorectum | AD | 9.40e-09 | 6.05e-01 | -0.0842 |
| 51253 | MRPL37 | HTA11_7862_2000001011 | Human | Colorectum | AD | 9.72e-07 | 5.38e-01 | -0.0179 |
| 51253 | MRPL37 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.16e-16 | 6.08e-01 | 0.096 |
| 51253 | MRPL37 | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.04e-04 | 4.71e-01 | 0.0528 |
| 51253 | MRPL37 | HTA11_7663_2000001011 | Human | Colorectum | SER | 2.59e-06 | 6.54e-01 | 0.0131 |
| 51253 | MRPL37 | HTA11_6801_2000001011 | Human | Colorectum | SER | 3.54e-06 | 6.92e-01 | 0.0171 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MRPL37 | SNV | Missense_Mutation | rs184402036 | c.1018N>A | p.Val340Met | p.V340M | protein_coding | tolerated(0.08) | benign(0.131) | TCGA-A5-A0GA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | taxol | PD | |
| MRPL37 | SNV | Missense_Mutation | c.817G>A | p.Val273Met | p.V273M | protein_coding | tolerated(0.16) | benign(0.055) | TCGA-A5-A0GB-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| MRPL37 | SNV | Missense_Mutation | novel | c.301N>T | p.Asp101Tyr | p.D101Y | protein_coding | deleterious(0) | possibly_damaging(0.736) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MRPL37 | SNV | Missense_Mutation | rs577122434 | c.790N>A | p.Asp264Asn | p.D264N | protein_coding | tolerated(0.13) | benign(0.069) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| MRPL37 | SNV | Missense_Mutation | novel | c.979N>T | p.Leu327Phe | p.L327F | protein_coding | tolerated(0.72) | benign(0.049) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MRPL37 | SNV | Missense_Mutation | novel | c.375N>T | p.Lys125Asn | p.K125N | protein_coding | tolerated(0.19) | probably_damaging(0.995) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MRPL37 | SNV | Missense_Mutation | novel | c.179N>C | p.Phe60Ser | p.F60S | protein_coding | tolerated_low_confidence(0.06) | benign(0.009) | TCGA-AP-A1E1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MRPL37 | SNV | Missense_Mutation | novel | c.31N>A | p.Ala11Thr | p.A11T | protein_coding | deleterious_low_confidence(0.05) | benign(0.12) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD | |
| MRPL37 | SNV | Missense_Mutation | c.734N>G | p.Ile245Ser | p.I245S | protein_coding | deleterious(0) | benign(0.415) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| MRPL37 | SNV | Missense_Mutation | novel | c.1144C>A | p.Leu382Ile | p.L382I | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |